12:00 AM
 | 
Jan 10, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Status

CK-2017357: Phase IIa started

Cytokinetics began a double-blind, crossover, U.S. Phase IIa trial in up to 78 patients with generalized MG. Patients will receive oral 250 and...

Read the full 95 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >